Work

Report-Defined FDG-PET/CT Positivity Is Common Across the Clinical Spectrum of Well-Differentiated Pulmonary Neuroendocrine Tumors

Year: 2026
Type: article
Study design: Observational Study
Abstract: Background/Objectives: The clinical significance of 18F-fluorodeoxyglucose (FDG) uptake in well-differentiated pulmonary neuroendocrine tumors (WD-PulNETs) remains uncertain. We assessed the prevalence of FDG positivity in routine clinical practice. Methods: This multicenter retrospective cohort included histologically confirmed typical or atypical pulmonary carcinoids. FDG PET/CT was classified as positive or negative according to the original nuclear-medicine report. Results: Of 91 WD-PulNETs patients, 81 had sufficient data for analysis. The cohort included 67 patients (82.7%) with typical carcinoids and 14 (17.3%) with atypical carcinoids. FDG PET/CT was performed in 50 patients (61.7%), of whom 46 (92.0%; 95% CI, 81.2–96.8%) had report-defined FDG positivity in the primary pulmonary tumor. FDG positivity was observed in 39 of 42 patients (92.9%) with typical carcinoids and 7 of 8 (87.5%) with atypical carcinoids. Comparisons between patients who underwent FDG PET/CT and those who did not revealed no statistically significant differences in most evaluated clinicopathological characteristics. However, somatostatin analogue treatment was more frequent among patients who underwent FDG PET/CT (35.6% vs. 7.7%; p = 0.011). Conclusion: Report-defined FDG positivity was highly prevalent across the spectrum of WD-PulNETs, including typical carcinoids. Potential selection bias and the small number of patients preclude firm conclusions about its discriminatory or prognostic significance.
Source: Biomedicines
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,137
OpenAlex ID: W7221087682
FWCI:
Cites: 20
Cited by:
Related to: 10